Acadia Pharmaceuticals
ACAD
186 hedge funds and large institutions have $2.26B invested in Acadia Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 63 increasing their positions, 56 reducing their positions, and 34 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 56
1.22% more ownership
Funds ownership: 96.01% → 97.22% (+1.2%)
1% more funds holding
Funds holding: 184 → 186 (+2)
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
5% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $25.7M
9% less capital invested
Capital invested by funds: $2.49B → $2.26B (-$233M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$219M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$71.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.2M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$30.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$38.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$33.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$22.9M |
| 4 |
PP
PDT Partners
New York
|
-$10.6M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$9.08M |
ACAD Hedge Fund Activity: Q4 2018 in Review
186 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2018, worth a combined $2.26B — down 9.4% from $2.49B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ACAD positions and 34 closed out — a net gain of 3 holders — while 63 added to existing stakes and 56 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $219M. The largest seller was State Street, cutting an estimated $38.8M.
- 186 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2018, up from 184 in Q3 2018.
- Funds reported $2.26B of Acadia Pharmaceuticals stock for Q4 2018, down 9.4% quarter-over-quarter.
- 37 funds opened new Acadia Pharmaceuticals positions in Q4 2018 and 34 closed out, a net change of +3 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2018 was Baker Bros. Advisors, an estimated $219M added.
- The largest Acadia Pharmaceuticals seller in Q4 2018 was State Street, an estimated $38.8M sold.
Based on aggregated 13F filings for Q4 2018.